Liver-Directed Recombinant Adeno-Associated Viral Gene Delivery Rescues a Lethal Mouse Model of Methylmalonic Acidemia and Provides Long-Term Phenotypic Correction
Year: 2010
Type: article
Abstract: Methylmalonic acidemia is an autosomal recessive metabolic disorder caused by a deficiency in the mitochondrial enzyme, methylmalonyl-CoA mutase (MUT). In this study, Carrillo-Carrasco and colleagues demonstrate that a single intrahepatic injection of AAV8 encoding the Mut gene under control of the liver-specific thyroxine-binding globulin promoter is sufficient to rescue Mut−/− mice from neonatal lethality and provides long-term phenotypic correction. Methylmalonic acidemia is a severe metabolic disorder caused by a deficiency of the ubiquitously expressed mitochondrial enzyme, methylmalonyl-CoA mutase (MUT). Liver transplantation has been used to treat a small number of patients with variable success, and whether liver-directed gene therapy might be employed in such a pleiotropic metabolic disorder is uncertain. In this study, we examined the therapeutic effects of hepatocyte-directed delivery of the Mut gene to mice with a severe form of methylmalonic acidemia. We show that a single intrahepatic injection of recombinant adeno-associated virus serotype 8 expressing the Mut gene under the control of the liver-specific thyroxine-binding globulin (TBG) promoter is sufficient to rescue Mut–/– mice from neonatal lethality and provide long-term phenotypic correction. Treated Mut–/– mice lived beyond 1 year of age, had improved growth, lower plasma methylmalonic acid levels, and an increased capacity to oxidize [1-13C]propionate in vivo. The older treated mice showed increased Mut transcription, presumably mediated by upregulation of the TBG promoter during senescence. The results indicate that the stable transduction of a small number of hepatocytes with the Mut gene can be efficacious in the phenotypic correction of an inborn error of organic acid metabolism and support the rapid translation of liver-directed gene therapy vectors already optimized for human subjects to patients with methylmalonic acidemia.
Source: Human Gene Therapy
DOI: 10.1089/hum.2010.008
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2031457189
